| Income Statement | 2026-06-30 | |||
|---|---|---|---|---|
| Collaboration revenue | 148 | |||
| Research and development cost | 39,377 | |||
| General and administrative | 11,657 | |||
| Total operating expenses | 51,034 | |||
| Loss from operations | -50,886 | |||
| Interest income | 4,189 | |||
| Interest expense | 210 | |||
| Sublease income - related party | 0 | |||
| Change in fair value of simple agreement for future equity | 5,556 | |||
| Total other (expense) income, net | -1,577 | |||
| Net loss | -52,463 | |||
| Cumulative dividends on convertible preferred stock | 14,492 | |||
| Deemed dividend upon down-round of convertible preferred stock | 0 | |||
| Net loss allocable to common stockholders | -66,955 | |||
| Basic EPS | -2.32 | |||
| Diluted EPS | -2.32 | |||
| Basic Average Shares | 28,908,277 | |||
| Diluted Average Shares | 28,908,277 | |||
Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. (PBLS)